News
ARUXF
0.017
NaN%
--
Acrux Seeks ASX Quotation for New Shares Issued Under Employee Scheme
TipRanks · 06/25 05:17
Acrux Director Tim Oldham Increases Indirect Shareholding via Rights Exercise
TipRanks · 06/02 04:27
Acrux Director Increases Stake Through Exercise of Vested Rights
TipRanks · 06/01 23:54
Acrux Director Increases Shareholding Through Exercise of Equity Rights
TipRanks · 06/01 23:54
Acrux Performance Rights Lapse Trims Potential Share Dilution
TipRanks · 06/01 23:51
Acrux Details Milestone Structure for Australian Lenzetto Licensing Deal
TipRanks · 05/29 02:37
Acrux Expands Lenzetto Licensing to Australia in Deal Worth Up to AUD 5.4m
TipRanks · 05/27 23:18
Acrux Plans Major Equity Issue to Bolster Capital Base
TipRanks · 05/11 01:02
Acrux Secures $1.6m Placement to Advance Female Testosterone Program
TipRanks · 05/11 01:02
Acrux Seeks Trading Halt Ahead of Proposed Capital Raising
TipRanks · 05/07 00:18
Acrux Secures $0.55m Advance on FY26 R&D Tax Incentive to Support HRT Development
TipRanks · 03/11 23:18
Acrux Performance Rights Lapse After Reaching Expiry
TipRanks · 02/26 00:43
Acrux Posts Strong Half-Year Profit Rebound Despite Lower Asset Backing
TipRanks · 02/25 00:35
Acrux Lifts Cash and Revenue as It Refocuses Portfolio on Higher-Value Therapies
TipRanks · 01/28 23:38
Acrux Divests US Rights for Prilocaine and Lidocaine Cream
TipRanks · 12/11/2025 23:28
Acrux Director Acquires Significant Unlisted Options
TipRanks · 12/03/2025 02:07
Acrux Director’s Interest Update: Significant Rights Acquisition
TipRanks · 12/03/2025 00:58
Acrux Director Acquires Unlisted Rights, Aligning Interests with Company Goals
TipRanks · 12/03/2025 00:58
Acrux Ltd Announces Director’s Interest Change
TipRanks · 12/03/2025 00:57
Acrux Director Acquires Additional Unlisted Rights
TipRanks · 12/03/2025 00:47
More
Webull provides a variety of real-time ARUXF stock news. You can receive the latest news about Acrux Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ARUXF
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.